Week of Feb 5th-9th, 2018
Check back often for weekly updates
INTERNAL GRANT OPPORTUNITIES
Internal Funding Opportunities & Limited Submission Grants:
A. Alfred Taubman Medical Research Institute – Innovation Programs: Phenotyping in the Clinical Setting (Award amount variable, rolling deadline).
The Taubman Institute is seeking to support new or existing teams of scientists to develop novel and impactful approaches to integrate their research programs into the clinic setting. The goal is to perform systematic, multiscale phenotyping to gain insights into individual variation in the susceptibility, progression, course, or outcomes of disease. The institute will partner with investigators to support the development and implementation of their research programs. This will include, but not be limited to, development of a research plan, identification of research partners within and external to U-M, infrastructure and database development, support for clinician and ancillary personnel in the clinic, clinical data collection, biological specimen collection, remote data collection, initiation of research plan, and data analysis. Our goal is to make every patient a research subject, and to define the genetic, environmental, behavioral and other components of individuals that contribute to their distinct emergent property related to health and disease. The goal is to also utilize the data to stratified an individual in order apply interventions that lead to the prevention, improved treatment, or cure of disease. The institute anticipates investing up to $2.5 million per year to support the funded projects. What are the criteria for funding? Impact on improving the lives of patients; Innovation in understanding the variability in onset or progression of disease, and reasons for differential response to treatment; Potential for future funding by the NIH or other external agencies; Potential for increased reimbursement for care by insurance companies, or cost savings to the medical system; and, Enhanced interactions with basic or other science disciplines (teams). Letter of intent: Description of the proposed program. Who is going to work together and what will be their roles? Have you worked together in the past? Where do you want to perform this work? What infrastructure is needed to accomplish the goals? Who will you need to partner with to succeed? What are the present barriers to your success? What are your plans for downstream funding? Note: not all of these points must be addressed in the LOI. We seek to understand your vision for bringing science into the clinic. The main request here is for an outline of what you want to do and why it will be impactful. There is no deadline. Letters of intent are accepted on a rolling basis, and should be submitted to managing director Grace Wu (firstname.lastname@example.org). We encourage questions. You may contact us with written questions through Grace Wu (email@example.com). We’re happy to meet with individuals or teams to discuss ideas.
Michigan-Israel Partnership for Research and Education Collaborative Research Grant Application – Request for Applications ($100,000 award, deadline March 1st, 2018).
New Deadline: Extended to March 1, 2018. A message relayed by the U-M Office of Research on behalf of the Michigan-Israel Partnership for Research and Education. In 2012, the University of Michigan (U-M) partnered with Technion Institute of Technology and the Weizmann Institute of Science to support meritorious research, foster innovation and spur collaboration in the areas of biomedical sciences. The partnership awards funding to support collaborative research projects led by scientists from the three institutions. Projects are awarded based on their potential to lead to scientific advances in understanding pathways of disease, novel diagnostics or therapeutics, as well as to peer-reviewed publication, and potentially other extramural support. Amount: Awards will be granted up to $100,000 US for two years for joint projects with an appropriate budget justification. Purpose: The Michigan-Israel Partnership for Research and Education, requests applications for collaborative research. The purpose of this Request for Applications (RFA) is to support meritorious research, to foster innovation, and to spur collaboration between three great academic institutions in the areas of biomedical sciences. Submit completed applications and all required material electronically in a single PDF format to CVC-Research@med.umich.edu by March 1, 2018 (extended deadline). Questions? Contact: Dr. David Pinsky (University of Michigan), firstname.lastname@example.org
U-M Fast Forward GI Innovation Fund ($100,000 award, deadline March 16th, 2018).
Please note that this a reposting of a grant first posted in the January 15-19, 2018 grants report
The U-M Fast Forward Gastrointestinal (GI) Innovation Fund is a three-year, $500,000+ fund supported by a donation from entrepreneur alumna Mary Petrovich and matched by the U-M Medical School’s Department of Internal Medicine and its Division of Gastroenterology, as well as the College of Engineering, where Ms. Petrovich received her undergraduate degree. The three-year program, which began in 2016, targets discovery and development of future technologies to help patients suffering from gastrointestinal disease. The U-M Fast Forward GI Innovation Fund supports early-stage research and commercialization activities such as those related to technology validation and establishing proof-of-concept, including pilot funding support for preliminary studies or development activities that will lead to broader GI product applications. Importantly the fund seeks to engage interdisciplinary teams of researchers that leverage ideas and technologies across medicine, engineering, public health, and other key units engaged in biomedical research. The FFMI team has assembled a GI Fund Advisory Board of faculty, industry, and commercialization experts who review proposals and provide mentorship for the funded teams. The award ranges are estimates and actual funding levels will be project-specific. Two tiers of funding are available: Tier I Awards – $25-$50K – fund projects that address a discrete milestone that is critical to the advancement of research to the point of product development. Tier II Awards – $75-$100K – fund projects with specific milestones for proof-of-concept and later-stage translational studies Proposal Submissions Due March 30, 2018. Note: A pre-submission application and meeting with FFMI staff is REQUIRED and must be completed on or before March 16, 2018.
U-M Center for the Discovery of New Medicines ($50,000 award, Pre-application deadline March 23rd, 2018).
Twice per year, the Center for the Discovery of New Medicines (CDNM) provides grant awards of up to $50,000 each for drug discovery research in all therapeutic areas. Preference will be given to studies on novel drug targets with a clear medical need and commercial viability. The expectation is that 90 percent of awarded funds will be used in the following CDNM-associated core laboratories to accelerate the discovery process: Center for Chemical Genomics; Center for Structural Biology; Vahlteich Medicinal Chemistry Core; Pharmacokinetics Core. Deadlines: A pre-submission application and meeting with the CDNM team must be completed on or before Friday March 23rd, 2018. A budget meeting with the CDNM-associated core in which funds will be requested for use must be completed on or before Friday April 6th, 2018. The submission deadline for the full proposal will be on Friday April 20th at 5:00 PM EST. All applications must submitted through competition space. Please email Ashley Schork email@example.com with any questions and to schedule a pre-submission meeting.
Limited: U-M will internally select eight (8) concepts to bring to the foundation for feedback. U-M will then put forward up to two of the eight as fuller Phase I proposals for the May 1 deadline.
The Research Program seeks to benefit humanity by supporting projects in two specific areas (1) medical research and (2) science and engineering, that are distinctive and novel in their approach, question the prevailing paradigm, or have the potential to break open new territory in their field. Past grants have been awarded to major universities, independent research institutions, and medical schools to support pioneering biological and physical science research and engineering, including the development of promising new technologies, instrumentation or methodologies. Questions: For more information regarding the review process and best practices in preparing your concept paper, please direct them to Maureen Martin (734-647-6074) in Foundation Relations. Link to Foundation Relations Keck information website. Review Process & Best Practices (Med School only) Joe Piffaretti. For questions regarding the internal competition deadline or internal submission process, please direct them to Tricia Ebright at UMOR.
EXTERNAL GRANT OPPORTUNITIES
American Diabetes Association –
- Pathway to Stop Diabetes Initiator Award – INI ($1,625,000 award with 30% IDC’s, deadline July 2nd, 2018).https://professional.diabetes.org/meetings/pathway-stop-diabetes%C2%AE Pathway to Stop Diabetes is a bold, innovative initiative designed to radically transform diabetes research. Pathway seeks to bring new investigators and new perspectives to diabetes research. Supporting scientists with different backgrounds and experience is critical to achieving that objective. Pathway accepts nominations for exceptional investigators with medical and scientific backgrounds who propose innovative basic, clinical, translational, behavioral, epidemiological and health services research relevant to any type of diabetes, diabetes-related disease state or complication. Description: This two-phased award is designed to support the transition of scientists from mentored training to independent research faculty. Support: Awards provide two distinct phases of research support: Phase 1 provides up to two years of support for mentored training at a maximum of $100,000 per year (including 10% indirect costs), Phase 2 provides up to five years of support for independent research at a maximum of $325,000 per year (including 30% indirect costs). Maximum combined support for Phase 1 and Phase 2 is $1,625,000. Deadline: July 2, 2018 for January 1, 2019 funding.
- Pathway to Stop Diabetes Accelerator Award – ACE ($1,625,000 award with 30% IDC’s, deadline July 2nd, 2018). https://professional.diabetes.org/meetings/pathway-stop-diabetes%C2%AE Pathway to Stop Diabetes is a bold, innovative initiative designed to radically transform diabetes research. Pathway seeks to bring new investigators and new perspectives to diabetes research. Supporting scientists with different backgrounds and experience is critical to achieving that objective. Pathway accepts nominations for exceptional investigators with medical and scientific backgrounds who propose innovative basic, clinical, translational, behavioral, epidemiological and health services research relevant to any type of diabetes, diabetes-related disease state or complication. Description: This award is designed to support exceptional, independent early-career researchers who have distinguished themselves as promising investigators and are in the beginning stages of establishing successful, sustainable diabetes research programs. Support: Awards provide five years of research support at a maximum of $325,000 per year (including 30% indirect costs), for a total of $1,625,000. Deadline: July 2, 2018 for January 1, 2019 funding
- Pathway to Stop Diabetes Visionary Award – VSN ($1,625,000 award with 30% IDC’s, deadline July 2nd, 2018). https://professional.diabetes.org/meetings/pathway-stop-diabetes%C2%AE Pathway to Stop Diabetes is a bold, innovative initiative designed to radically transform diabetes research. Pathway seeks to bring new investigators and new perspectives to diabetes research. Supporting scientists with different backgrounds and experience is critical to achieving that objective. Pathway accepts nominations for exceptional investigators with medical and scientific backgrounds who propose innovative basic, clinical, translational, behavioral, epidemiological and health services research relevant to any type of diabetes, diabetes-related disease state or complication. Description: Awards are designed to support established, experienced investigators with strong records of outstanding productivity in fields outside of diabetes who are interested in applying their considerable skills and expertise to diabetes research. These awards are highly competitive and intended to support particularly innovative and transformational ideas that have the potential to have an exceptional impact in diabetes. Support: Awards provide two distinct phases of research support: Phase 1 provides up to three years of support at a maximum of $325,000 per year (including 30% indirect costs), Phase 2 provides up to two years of support at a maximum of $325,000 per year (including 30% indirect costs). Phase 2 is contingent upon demonstration of significant contributions to the field of diabetes research in Phase 1. Maximum combined support for Phase 1 and Phase 2 is $1,625,000. Deadline: July 2, 2018 for January 1, 2019 funding.
Prostate Cancer Foundation – Request for Team Science Applications for 2018 PCF Challenge Award ($1 million award, deadline April 23rd, 2018). https://www.pcf.org/c/open-rfas/ The Prostate Cancer Foundation (PCF) is pleased to announce a Request for Team Science Applications for PCF Challenge Awards for investigations of metastatic, lethal prostate cancer. High risk, currently unfunded projects are most desired. We especially seek applications conducting research in VA hospitals where research directly affects veterans with advanced prostate cancer. PCF Challenge Awards: Composed of a team of at least three (3) investigators from non-profit academic research centers, including one young investigator. Support large-scale research projects concerning metastatic, lethal prostate cancer over a duration of two years. Provide up to a total of $1 million per team. Cover only direct research costs and travel to the Annual PCF Scientific Retreat. Research proposals in the following topic areas are preferred: Immunotherapy for the treatment of metastatic, lethal prostate cancer. Targeted radionuclide therapy for advanced prostate cancer. New systemic precision treatments for metastatic, lethal prostate cancer including those targeting the currently ‘undruggable’. First-in-field research on new targets for systemic treatment of metastatic, lethal prostate cancer. Mechanisms of resistance to current and investigational drugs targeting the androgen receptor and androgen axis, immune system, chemotherapy, and other targeted agents. Correlative research around either clinical trials of novel agents or strategies or standard of care. Developing or validating biomarkers that guide therapy in patients or further our understanding of the mechanisms by which therapies work. Tumor microenvironment signaling related to cancer progression including the immune component. New bioinformatics technologies for analysis of genomic data and big data of clinical outcomes. Deadline: April 23, 2018, 3:00 pm, Eastern Daylight Time (EDT)
- 2018 ASPIRE Breast Cancer Research Awards Program ($666,666 award, deadline April 27th, 2018). https://www.aspireresearch.org/onc/index.html The ASPIRE Breast Cancer Research Awards Program underscores Pfizer’s commitment to supporting investigators in advancing their academic research in the field of breast cancer. Mission: The mission of the ASPIRE Awards program is to support clinical research in the field of breast cancer through a competitive grants program. Background: This program is to support continuous medical research to maximize the available therapies by improving medical knowledge and clinical management of the disease. Request for Proposals: Pfizer invites investigators to apply for the 2018 ASPIRE Breast Cancer Research Awards program through submission of innovative clinical research proposals designed to accomplish the mission of advancing knowledge of select Pfizer compounds in the treatment and disease management of breast cancer. Scope of Research Areas: Pfizer is interested in supporting clinical studies in breast cancer, focusing in the following areas: In hormone receptor positive (HR+) advanced breast cancer, safety and efficacy profile of palbociclib/hormone therapy given concurrently with radiation in patients with bone disease In HER2- advanced breast cancer, safety and efficacy profile of talazoparib novel combination (except CDK4/6 inhibitors) in patients with HRD/DDR deficiency; In HER2- advanced breast cancer, safety and efficacy profile of gedatolisib plus talazoparib combination in appropriate patients; In early stage breast cancer setting, translational end point driven study to explore potential effect of gedatolisib on immune system in regard to PD-1, PD-L1, TILs, and other appropriate markers, with or without an immunotherapy agent. In addition, the following would be of interest: incorporation of a correlative/biomarker component into the proposed clinical study using paired biopsy samples, e.g. pre- and post- treatment, liquid biopsy, or PK/PD biomarkers to explore potential mechanism of resistance or response, synergistic effect, and etc. Available Awards: 2018 ASPIRE Breast Cancer Research Awards intend to fund 4 to 6 clinical studies within research scope, for a total of approximately 4 million US dollars. It is open to US investigators. Selection of research proposals will be performed by an independent external review panel of experts. Stage 1 Application deadline: April 27, 2018 (by 11:59pm EST in the United States), NO EXCEPTIONS.
- Emerging Treatments and Preventative Care Strategies for Patients With Inflammatory Bowel Disease – IBD ($350,000 award, deadline March 16th, 2018).
Clinical Area: Inflammatory Bowel Disease. Specific Area of Interest for this CGA: The intent of this CGA is to encourage organizations to design educational programs to reach gastroenterologists and gastroenterology fellows, nurse practitioners, physician assistants, and all other healthcare professionals involved in the care and treatment of adult patients with inflammatory bowel disease (IBD). As research has progressed into the pathogenesis of the IBD spectrum, new therapeutic targets and strategies have been discovered. Additionally, research has demonstrated that IBD patient do not always receive the preventive services they need. This is particularly important for patients requiring long-term immune-suppressive therapy who are at increased risk of infections. Adherence to appropriate vaccination guidelines can help mitigate this risk, yet a number of studies have demonstrated poor compliance with vaccination guidelines. Programs aimed at increasing awareness and understanding of emerging therapies or foster an understanding and implementation of innovative preventative care strategies in the treatment of adult patients with IBD will be considered. Organizations responding to this CGA should recognize these and other priority knowledge gaps in mind when designing programs. Programs with the highest likelihood of improving clinical gastroenterologists’ and gastroenterology fellows’, nurse practitioners’, physician assistants’, and all other healthcare professionals’ understanding of the current vaccination guidelines, the importance of vaccination in the care of IBD patients, and/or improving the health care team’s understanding of emerging therapies will be given the highest priority. All activity types will be considered through this CGA, including live events, satellite symposia, workshops, online courses, print materials, and other enduring materials, including published proceedings. Efforts should be made to encourage interaction, incorporate real-world patient case discussions, and provide opportunities to extend and reinforce learning opportunities beyond the live setting. Individual projects requesting up to $350,000 will be considered. Grant application due date: March 16, 2018.
- Adjuvant Treatment in Retinal Cell Carcinoma – RCC ($250,000 award, deadline March 15th, 2018). https://www.pfizer.com/purpose/medical-grants/process Clinical Area: Renal Cell Carcinoma (RCC). Specific Area of Interest for this CGA: It is our intent to support continuing education programs that increase the awareness and understanding of Advances in Adjuvant Treatment in Renal Cell Carcinoma (RCC). Responses to this should broadly consider what happens after a patient is diagnosed with RCC and at high risk for recurrence and why an adjuvant option may be considered. Example topics may include mechanism of disease, recurrence rates, shared-decision making, oncologist/urologist interplay, and risk stratification. The content or format of a CME activity or its related materials must promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. The target learner audiences include: Urologists, Medical Oncologists, Surgeons, Health System Pharmacists, Urological & Oncology Nurses. All CME/CE activity types will be considered through this CGA including but not limited to; national or regional symposia, workshops, regional community series; online courses & tools, print materials and other enduring materials. The typical grant maximum under this CGA will be up to $250,000. Larger proposals will be considered for funding if they include multiple activities such as several live events, enduring activities, and supportive materials and tools. Grant application due date: March 15, 2018.
- Understanding the Importance of Calcium and Vitamin D Supplementation for Aging Men ($200,000 award, deadline March 19th, 2018).https://www.pfizer.com/purpose/medical-grants/process Clinical Area: Male Bone Health: Importance of Calcium & Vitamin D Supplementation. Specific Area of Interest for this CGA: It is our intent to support projects that focus on increasing the awareness about elements essential to healthy ageing in men and the components that need to be managed to maintain. Primary focus should be on bone health and Calcium and Vitamin D supplementation. The target learner audiences include healthcare professionals with a focus on prevention and treatment of male osteoporosis, and General practitioners. All activity types will be considered through this CGA, however, web-based education and satellite symposia has particular interest. An activity taking place alongside the American Society for Bone and Mineral Research (ASBMR) Annual Meeting in September 2018 is also of particular interest. Efforts should be made to encourage interaction, incorporate patient case discussions, and provide opportunities to extend and reinforce learning beyond the live setting. The total available budget related to this CGA is $200,000.00 USD. The grant amount Pfizer will be prepared to fund will depend upon the evaluation of the proposal and costs involved and will be stated clearly in the approval notification. Grant application due date: March 19, 2018.
- Rheumatology ($160,000 award, deadline March 23rd, 2018). https://www.pfizer.com/purpose/medical-grants/request-proposals Clinical area: Rheumatology. Specific Area of Interest: It is our intent to support institutions with Rheumatology fellowship programs that have a strong focus on clinical practice, research, and education to further the understanding of Rheumatoid Arthritis and Psoriatic Arthritis. Grants will be awarded based on the strength of the requesting organization’s ability to provide training and mentorship to the fellow, as well as the strength of the program in supporting clinical training and research. Individual requests for fellowship grants up to $80,000 per year for up to two years will be considered. Funding is to be used as a salary supplement for a fellow at the recipient organization. Funding will be awarded to the organization, which will select the recipient. Applications due date: March 23, 2018.
Jacobs Foundation – Research Fellowship Program ($426,764 award, deadline March 18th, 2018).
The Jacobs Foundation Research Fellowship Program is a globally competitive fellowship program for early and mid-career researchers aiming at improving the learning, development and living conditions of children and youth or contributing to one of the Jacobs Foundation’s thematic priorities. This includes, but is not limited to educational sciences, psychology, economics, sociology, family studies, media studies, political sciences, linguistics, neurosciences, and medical sciences. Fellowships are awarded to the most highly talented and innovative young scholars and mid-career researchers. Funds from Jacobs Foundation Research Fellowships are awarded directly to the fellow’s institution and may be used over a three-year period by the fellow to partially cover the fellow’s salary and for any activity supporting the fellow’s research, such as assistant salaries, equipment, technical assistance, professional travel, or trainee support. Scholars who engage in interdisciplinary work on individual development and learning of children and youth, and who seek to combine genetic, epigenetic, neurobiological, behavioral and social levels of analysis, are particularly encouraged to apply. Besides providing fellows with independent and competitive funding, the program offers a wide range of non-financial benefits. Fellows are encouraged to interact with each other and make use of the Jacobs Foundation’s Conference Center Marbach Castle at Lake Constance (Germany) for short-term group retreats and workshops. Networking and alumni events will enrich the fellowships. Fellows are selected on the basis of their research accomplishments, creativity, and potential to become leaders in the scientific community through their contributions to the field of child and youth development. International relevance of the fellow’s planned work, the alignment of planned projects with the goals of the Jacobs Foundation, and the willingness to identify with our aims and to engage actively with us will also be selection criteria. Jacobs Early Career Research Fellowship Funding Amount: 150,000 CHF. Jacobs Advanced Research Fellowship Funding Amount: 400,000 CHF. Application deadline: The application and the recommendation letter have to be submitted until 18 March 2018, 23.59 CET.
Craig H. Neilsen Foundation –
- Psychosocial Research Studies and Demonstration Projects ($400,000 award, Letter of Intent deadline March 23rd, 2018). http://chnfoundation.org/how-to-apply/ This funding category is intended to support substantive studies that fill important gaps in the SCI field, that open new areas of SCI psychosocial research, or that develop and evaluate interventions to address psychosocial issues after SCI. Proposed submissions in this category should facilitate, expand or improve the translation of knowledge and/or the adoption of interventions and practices that will have a positive impact for those living with SCI. Based within a psychosocial framework, PSR Studies and Demonstration Projects can range from SCI epidemiological studies to interventions that will enhance clinical treatment, rehabilitation, habilitation and/or other related quality of life subsets. Funding for PSR Study and Demonstration Projects is for up to three years, $400,000 total costs. Letter of Intent (LOI) Submission Due via proposalCENTRAL: March 23, 2018 5:00 PM (Eastern Time).
- Psychosocial Research Pilot Grants ($200,000 award, Letter of Intent deadline March 23rd, 2018). http://chnfoundation.org/how-to-apply/ This funding category is intended to support Pilot studies that lay essential groundwork to inform future research, allow the PI to test the feasibility of novel methods and procedures and/or collect new data that can lead to or enhance larger-scale trials. Proposed Pilot projects should indicate how they will establish a new investigational program or take on “risk” balanced by high potential impact. Funding for PSR Pilot grants is for up to two years, $200,000 total costs. Letter of Intent (LOI) Submission Due via proposalCENTRAL: March 23, 2018 5:00 PM (Eastern Time).
- Psychosocial Research Postdoctoral Fellowships ($150,000 award, deadline March 23rd, 2018). http://chnfoundation.org/how-to-apply/ This funding is designed to encourage specialization in the field of SCI; Fellowships are intended to provide mentored training in SCI research to early-career investigators. The Fellowship Applicant (Fellow) should be mentored (or co-mentored) by an investigator experienced in SCI psychosocial research. Funding for Fellowships is $75,000 per year, for up to two years; $150,000 total costs. Letter of Intent (LOI) Submission Due via proposalCENTRAL: March 23, 2018 5:00 PM (Eastern Time)
National Hemophilia Foundation – Shire Clinical Fellowship Program ($200,000 award, deadline April 4th, 2018). https://www.hemophilia.org/Researchers-Healthcare-Providers/Research-Grant-Programs/NHF-Shire-Clinical-Fellowship-Program The NHF-Shire Clinical Fellowship Program, funded through the generous support of Shire, plc, is intended to increase the number of skilled clinicians committed to providing comprehensive care for individuals with bleeding disorders. The program is designed to provide licensed physicians with hands-on clinical training and prepare them for academic careers in bleeding disorders research. Mentored training takes place at highly-qualified hemophilia and/or thrombophilia treatment centers located throughout the United States. Through this program, award funding is provided to cover costs directly related to the training of physicians who show an interest in devoting their careers to the care of patients with hemophilia and other bleeding disorders. Selections are made by an independent peer review panel and award recipients are able to receive up to $100,000/year (for up to two years). Institutional Application Deadline: April 4, 2018. Candidate Application Deadline: April 4, 2018.
Cystic Fibrosis Foundation – Mental Health Coordinator Award ($150,000+ award with 8% IDC’s, deadline April 2nd, 2018).https://proposalcentral.altum.com/GrantOpportunities.asp?GMID=14 The overall purpose of the Mental Health Coordinator Award is to promote the development of a Collaborative Care Model (CCM) at CF Centers that incorporate a system for prevention, screening for and treatment of anxiety and depression. Thus, the award is designed to facilitate implementation of the depression and anxiety guideline recommendations. The focus of this Request for Applications (RFA) is to provide seed funding for a CF Mental Health Coordinator (MHC) to programs that have not previously received a MHC award. The MHC is expected to implement annual screening and follow-up; coordinate evidence-based treatment for depression and anxiety; develop and maintain a referral network of community-based mental health practitioners; and, serve as an educator and liaison for mental health care in CF for the CF Center, hospital or institution, community practitioners, and payers. This person will provide basic information about the common symptoms of depression and anxiety, provide follow-up for those individuals scoring in the elevated range, provide interventions to improve patients’/parents’ coping skills, and behavioral interventions for painful medical procedures. He/she will collect data on screening scores and subsequent assessment and follow-up, provision of interventions, and their outcomes. Additionally, he/she will indicate in the patient registry on the annual form if the screening has been completed for the individual with CF. Funding: The maximum award amount is $150,000 in direct costs plus eight percent (8%) indirect costs over three (3) years. Application Deadline: April 2, 2018.
Tuberous Sclerosis Alliance –
- Postdoctoral Fellowships ($150,000 award, Letter of Intent deadline May 7th, 2018). http://www.tsalliance.org/researchers/grants-and-funding/Duration: up to two years (can be shorter if appropriate for the project and the trainee). Maximum total costs of $75,000 per year ($150,000 total) inclusive of both direct and indirect costs. Postdoctoral fellowship awards may support any type of basic or translational research relevant to TSC that provides an outstanding opportunity for the trainee’s professional growth. Letters of Intent must be submitted no later than May 7, 2018, at 11:59 p.m. US EDT.
- Research Grants ($150,000 award, Letter of Intent deadline May 7th, 2018). http://www.tsalliance.org/researchers/grants-and-funding/ Duration: up to two years (can be shorter if appropriate for the project). Maximum total costs of $75,000 per year ($150,000 total) inclusive of both direct and indirect costs. Research plans should address one of the following four high-priority areas: Understanding phenotypic heterogeneity in TSC, i.e., research on genetic, biologic, or environmental factors that might explain why TSC is so different from person to person; Gaining a deeper knowledge of TSC signaling pathways and the cellular consequences of TSC deficiency; Improving TSC disease models, whether cell-based, tissue-based, or animal models; and, Developing clinical biomarkers or patient-reported outcome measures for TSC, particularly those that assess disease burden or stratify an individual’s risk of progression or developing specific manifestations of TSC. Letters of Intent must be submitted no later than May 7, 2018, at 11:59 p.m. US EDT.
Orphan Disease Center and LouLou Foundation – 2018 CDKL5 Program of Excellence Pilot Grant Program ($150,000 award, Letter of Intent deadline March 8th, 2018).
The ODC and Loulou Foundation CDKL5 Pilot Grant Program provides a one‐year grant for $150,000.00 (total cost) to support research related to CDKL5 Deficiency Disorder (CDD). The number of awards may vary. We are seeking grant applications that progress the discovery or development of treatments and/or a cure for CDKL5 Deficiency. We recognize, however, that many gaps exist in the basic understanding of CDKL5 and its role in neurologic development. Therefore, basic science projects that address these gaps are welcome as long as they are tethered to the development of a potential therapy. While the RFA is broad in scope, priority will be given to grants that cover the following areas: Novel therapeutic approaches for CDKL5 Deficiency Disorder (CDD), including but not limited to techniques in genome editing, RNA-based mechanisms, biologics, and small molecule repurposing. Approaches to validate phenotypes in CDKL5 function or disease pathophysiology through rescue of phenotypic deficits with pharmacological or genetic / gene therapy techniques. Phenotypic reversal in rodent models will focus on the use of adult (2 months of age or older) animals. In particular, approaches are encouraged which allow the identification of individual CDKL5 protein isoforms (arising from alternative splicing, alternative promoter usage, or post-translational modifications) which can rescue these phenotypes. Systems biology and computational modeling approaches to provide a deeper understanding of CDKL5 function, downstream effectors, signaling, protein: protein interactors, or modifiers, including regulators of CDKL5 gene expression (transcriptional, post-transcriptional/RNA processing, translational, post-translational). Novel imaging and functional approaches to phenotyping CDD in pre-clinical models or the clinical setting. A non-exclusive list of topics that would be responsive to this RFA is listed below: Functional/structural MRI; diffusion tensor imaging (DTI); Magnetic resonance spectroscopy (MRS); Stimulus-induced event-related potentials: impact of CDKL5 genetic / gene therapy or pharmacological interventions on deficits in stimulus-induced event potentials (visual, auditory, or other) in CDD disease models; Discovery and validation of CDKL5 biomarkers and their translation to the clinical setting. Eligibility: All individuals holding a faculty‐level appointment at an academic institution or a senior scientific position at a non-profit institution or foundation are eligible to respond to this RFA. Letter of intent deadline: March 8, 2018.
NINDS Center for SUDEP Research Pilot ($80,000 award, deadline March 14th, 2018).
The Center for SUDEP Research (CSR) has been established to study Sudden Unexpected Death in Epilepsy (SUDEP). This Epilepsy Center Without Walls includes over 40 clinicians and scientists from 14 institutes across the U.S. and U.K. This five-year research initiative is supported by the National Institute of Neurological Disorders and Stroke at the National Institutes of Health (NIH) and brings together many of the leaders in the field of SUDEP research. The CSR is composed of a multidisciplinary group of investigators with expertise in molecular biology, genetics, neuropathology, electrophysiology, brain imaging, epilepsy, respiratory physiology, cardiology, and bioinformatics. The team will be involved in nine projects that combine basic research and clinical findings with the common goal of quickly taking SUDEP lab results into the clinic. Pilot Projects: The CSR seeks novel pilot projects that will address the goal of understanding and eliminating SUDEP. This pilot program will award grants to national and international researchers submitting innovative proposals that compliments and expands on the SUDEP research proposed in the CSR. The CSR plans to support one clinical pilot project (clinical trials will not be funded through this mechanism, but studies involving human subjects are allowed) and one basic research project. Infrastructure building applications are discouraged and applications need to have robust scientific hypotheses. Utilizing current existing CSR Cores and expertise is strongly recommended. Successful applicants will be expected to work collaboratively with the CSR investigators. Budget: Requests may be made for up to $80,000 in total (direct+indirect) costs paid over 1 year. Submission of application: All applications should be submitted to: http://webgrants.case.edu/ and must be received by 5:00pm EDT, Wednesday, March 14, 2018.